NCT05456165 - Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer | Biotech Hunter

Timeline

Start Date

May 19, 2022

Primary Completion Date

September 1, 2022

Study Completion Date

September 1, 2022

Conditions

Colonic NeoplasmsColorectal Neoplasms

Interventions

DRUG

GRT-C901

An individualized neoantigen cancer vaccine using an adenovirus vector administered via intramuscular (IM) injections at Visit 1 and boost at Visit 6.

DRUG

GRT-R902

An individualized neoantigen cancer vaccine using a self-amplifying mRNA (samRNA) vector administered via IM injection at Visits 2, 4, 9, and 12.

DRUG

Atezolizumab

Dose of 1680 mg administered once every 4 weeks (Q4W) via intravenous (IV) infusion at Visits 1-13.

DRUG

Ipilimumab

Dose of 30 mg administered via subcutaneous (SC) injection only with the first dose of GRT-C901 at Visit 1 and GRTR902 at Visit 2.

DRUG

Adjuvant chemotherapy

Administered according to standard of care.

Trial Locations (3)

10016

NYU Langone Health, New York

45229

Christ Hospital Cancer Center, Cincinnati

48201

Barbara Ann Karmanos Cancer Institute, Detroit